Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
204.2 USD | +2.91% | +0.54% | -10.17% |
29/04 | Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy | MT |
29/04 | US FDA publishes final rule for laboratory developed tests | RE |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.17% | 17.21B | B | ||
-14.58% | 85.02B | B- | ||
+15.05% | 82.37B | C+ | ||
+10.49% | 29.29B | C+ | ||
-0.75% | 16.7B | A- | ||
-31.40% | 11.8B | - | - | |
+2.29% | 12.15B | A- | ||
+31.86% | 12.12B | B- | ||
-1.53% | 12.13B | A- | ||
-8.00% | 11.67B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LH Stock
- Ratings Laboratory Corporation of America Holdings